The rising use of glucagon-like peptide-1 (GLP ... of drug that mimics the glucagon-like peptide-1 hormone. It stimulates insulin secretion and reduces appetite, helping to control blood sugar and ...

For this study, researchers analyzed U.S. federal research data in which people were asked about their GLP-1 prescriptions. Results showed that among people without diabetes, GLP-1 drug use rose ...

For this study, researchers analyzed U.S. federal research data in which people were asked about their GLP-1 prescriptions. Results showed that among people without diabetes, GLP-1 drug use rose ...

Novo Nordisk's GLP-1 receptor ... alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use for the versatile drug class. The small, 48-subject study ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

However, it is important to note that the study's cross-sectional design means these findings are correlational, not causal; the data do not show that these factors cause interest in GLP-1 use.

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs ... for, use is not consistent. The design of the study ...

(CNN) — The use of ... a new study finds, even though there’s little information on the drugs’ safety and effectiveness for the condition. The family of medications called GLP-1 receptor ...

Share on Pinterest A new study shows GLP-1 drugs liraglutide ... Wegovy is approved for use in weight management. Semaglutide drugs are available as both oral tablets and injections.